FDA Webview Site FDA Review Site FDA Updater Site
header.gif
Username:
Password:
 

human drugs
animal drugs
biologics
eirs 483s
medical devices
marketing
email
search our site
  
FDA-RELATED NEWS
 
  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Next >>
 
TXT Senators Demand HHS Reverse Autism-Related Web Site Changes
03/17/2026
 
 
TXT FDA Enforcement Year in Review
01/27/2026
 
 
TXT Vanda Hetlioz sNDA Not Approvable, FDA Says
01/08/2026
 
 
TXT FDA Warns Apotex Canadian Manufacturing Site
11/05/2025
 
 
TXT FDA Takes Actions to Curb Autism
09/22/2025
 
 
TXT GDUFA Post-Warning Letter Meeting Guidance
06/18/2025
 
 
TXT Can Surprise Foreign Drug Inspections Boost Safety?
06/10/2025
 
 
TXT FDA Policy Head on Major Trump Changes at FDA
05/19/2025
 
 
TXT Vanda Tradipitant Scheduling Order Out
05/01/2025
 
 
TXT Little Trust in New Health Leaders: Poll
04/30/2025
 
 
TXT Hill Staffer Graham Appointed to FDA Policy Office
04/16/2025
 
 
TXT Celltrion’s Humira Biosimilar Now Interchangeable: FDA
04/16/2025
 
 
TXT Marks’ Firing Challenges RFK Jr.’s Fitness for Office
03/31/2025
 
 
TXT DOGE-Targeted FDA Lab to Remain Open
03/05/2025
 
 
TXT FDA Requires New Seizure Warning for Parkinson’s Drugs
03/23/2026
 
 
TXT Legal Update Highlights FDA’s Guide on 3 Year Exclusivity
03/23/2026
 
 
TXT Influencers’ Drug Promotions Pose Public Health Risks: JAMA
03/23/2026
 
 
TXT ICH Signals New Standards for Advanced Drug Manufacturing
03/23/2026
 
 
TXT Lilly Retatrutide Meets Key Primary, Secondary Endpoints
03/19/2026
 
 
TXT Warning Letter Cites ‘Right-to-Try’ Law
03/19/2026
 
 
TXT Sarepta to Submit Amondys 45 and Vyondys 53 sNDAs
03/19/2026
 
 
TXT Novo Nordisk’s High-Dose Wegovy Approved
03/19/2026
 
 
TXT Rare Disease Advocates Stage ‘Funeral’ at FDA Headquarters
03/19/2026
 
 
TXT Multiple Avertix Medical Violations Cited
03/18/2026
 
 
TXT India’s Patcos Markets Insanitary OTC Drugs with CGMP Issues: FDA
03/18/2026
 
 
TXT Guide Aims to Expand Non-Animal Methods in Drug Development
03/18/2026
 
 
TXT Some Agreements in MDUFA 6 Negotiations
03/18/2026
 
 
TXT FDA Approves J&J’s Icotyde for Plaque Psoriasis
03/18/2026
 
 
TXT Experts Urge 32 FDA Transparency Reforms in New JAMA Viewpoint
03/18/2026
 
 
TXT FDA Updates Guidance on Pyrogen and Endotoxin Testing
03/18/2026
 
 
TXT Oralabs Cited for CGMP Violations
03/17/2026
 
 
TXT API Deviations Seen in Flowchem Pharma Inspection
03/17/2026
 
 
TXT BioMarin Halts Dosing in Some Voxzogo Mid-Stage Trials
03/17/2026
 
 
TXT Quality Control, Microbial Risks Flagged at API Manufacturer
03/17/2026
 
 
TXT Praise for FDA Bayesian Methodology Draft Guidance
03/17/2026
 
 
TXT FDA Draft Guidance on Responses to FDA-483s Explained
03/17/2026
 
 
TXT FDA Flags Sterility, Contamination Control Issues at India Plant
03/16/2026
 
 
TXT FDA Updates Internal Procedures for Handling Supplements
03/16/2026
 
 
TXT FDA Will Review Ketamine-Based Drug Without New Trials: NRx
03/16/2026
 
 
TXT Telix Resubmits NDA for Brain Cancer Imaging Agent Pixclara
03/16/2026
 
 
TXT FDA Warning Letters Surge in FY2025, Report Finds
03/13/2026
 
 
TXT Enforcement, Advertising Oversight Shape Regulatory Landscape: Legal Update
03/13/2026
 
 
TXT Uncertainty for Gene Therapy, Rare Disease & Vaccines in Prasad Exit Wake
03/13/2026
 
 
TXT Concerns Mount Over Fast Drug Review Voucher Program
03/13/2026
 
 
TXT Lilly Warns of Risk in Compounded Tirzepatide/Vitamin B12
03/12/2026
 
 
TXT Attorneys Discuss New FDA Draft NCI Guidance
03/12/2026
 
 
TXT Continue Modernizing Foreign Inspections: Study
03/12/2026
 
 
TXT FDA Draft Guidance for Medical Devices Intended for Weight Loss
03/12/2026
 
 
TXT AI Has Saved FDA 17,000 Hours: Makary
03/12/2026
 
 
TXT Sen. Johnson Probing FDA Rare Disease Denials
03/11/2026
 
 
TXT FDA Opens New, Searchable Adverse Event Platform
03/11/2026
 
 
TXT 4 Major Issues ‘Plaguing’ FDA: Newsweek
03/11/2026
 
 
TXT FDA Posts 483 Related to New Novo Nordisk Warning Letter
03/11/2026
 
 
TXT CGMP Violations in Tentamus India Inspection
03/11/2026
 
 
TXT Advita Ortho Hit with 7 QS Violations
03/11/2026
 
 
TXT FDA Flags Safety Reporting Lapses at U.K. Clinical Trial Site
03/10/2026
 
 
TXT Capricor’s Duchenne Cell Therapy BLA Resubmitted
03/10/2026
 
 
TXT FDA OKs Leucovorin for Ultra-Rare Brain Disorder, But Not Autism
03/10/2026
 
 
TXT CGMP Issues at Simtra BioPharma Solutions
03/10/2026
 
 
TXT Novo Nordisk PADE Reporting Violations
03/10/2026
 
 
TXT CGMP Violations at Fareva Morton Grove
03/10/2026
 
 
TXT Hims & Hers Super Bowl Ad Hit
03/10/2026
 
 
TXT FDA DTC Ad Crackdown Raises Legal Issues: Attorneys
03/10/2026
 
 
TXT Updated Guidance Clarifies Biosimilar Development Requirements
03/09/2026
 
 
TXT Incyte Gets ‘Complete Response’ Over Catalent Inspection Issues
03/09/2026
 
 
TXT Group urges Pfizer to Retract Threat on Drug Supplies
03/09/2026
 
 
TXT FDA Meets with States to Advance Canada Importation Plan
03/09/2026
 
 
TXT Ipsen Withdraws Tazverik Over Safety Data
03/09/2026
 
 
TXT FDA Cites Documentation Lapses at Maiva Pharma
03/06/2026
 
 
TXT Public Trusts FDA Career Scientists Over Agency Leadership
03/06/2026
 
 
TXT FDA Biologics Chief Vinay Prasad to Step Down in April
03/06/2026
 
 
TXT FDA Official Criticizes Advisory Committee Experts
03/06/2026
 
 
TXT Guidance Urges Comprehensive Responses to Inspection Findings
03/06/2026
 
 
TXT FDA Operations Chief Announces Retirement
03/05/2026
 
 
TXT Attorneys Review FDA’s New Inspection Approach for Devices
03/05/2026
 
 
TXT Regulate Outsourcing Ophthalmic Bevacizumab Products: Petition
03/05/2026
 
 
TXT Senate Committee Has More Drug Supply Questions
03/05/2026
 
 
TXT FDA Official Pushes Back in UniQure Dispute
03/05/2026
 
 
TXT FDA Approves Teclistamab Combination for Multiple Myeloma
03/05/2026
 
 
TXT ExThera Regulatory Chief Charged With Concealing Adverse Events
03/05/2026
 
 
TXT Petition Asks FDA to Investigate Mayo Robotic Mastectomy
03/05/2026
 
 
TXT Rep. Auchincloss Criticizes Commissioner’s Priority Voucher Program
03/04/2026
 
 
TXT Hoeg Recruits Petitioner Seeking New SSRI Warnings
03/04/2026
 
 
TXT Partial Hold on Myotonic Dystrophy Type 1 Therapy
03/04/2026
 
 
TXT FDA Posts Fujian Genohope FDA-483
03/04/2026
 
 
TXT FDA Denies Petition Seeking Accelerated Aging Therapies
03/04/2026
 
 
TXT Diasol Manufacturing Illegal Dialysis Disinfectants: FDA
03/04/2026
 
 
TXT BioMarin Natriuretic Peptide Petition Denied
03/04/2026
 
 
TXT Vanda Wins Long-Sought Hearing on Hetlioz sNDA for Jet Lag
03/03/2026
 
 
TXT Time to Update FDA SUPAC Guidances
03/03/2026
 
 
TXT ICH M14 Guide on Non-Interventional Study Principles Out
03/03/2026
 
 
TXT FDA Publishes ICH Postapproval Safety Data Guide
03/03/2026
 
 
TXT Fukuzyu FDA-483 Out
03/03/2026
 
 
TXT FDA Hits Novo Nordisk Over Ozempic Ad
03/03/2026
 
 
TXT Regenxbio’s Complete Response Letter Released
03/03/2026
 
 
TXT FDA Working on Peptide Accessibility: Politico
03/03/2026
 
 
TXT FDA Wants Randomized Trial for Huntington’s Gene Therapy
03/02/2026
 
 
TXT Pfizer CEO Concerned About FDA Vaccines Chief
03/02/2026
 
 
TXT Intellia Gets Hold Lifted on MAGNITUDE Phase 3 Trial in ATTR-CM
03/02/2026
 
 
TXT Ex-FDA Leaders Accuse Trump Admin of Distorting Contraceptive Science
03/02/2026
 
 
  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20  Next >>
 
The most authoritative FDA news analysis each week is found in the pages of Dickinson's FDA Review. Since 1984, this newsletter has been providing in-depth reports on the most significant FDA developments affecting the pharmaceutical, medical device, biologics and veterinary medicines industries. Unlike other media, FDA Review eliminates time-wasting minutia and presents in clear, concise language the essence of what's really important - and why. It is the publication that FDA officials themselves read. Delivered in the middle of each week, FDA Review presents:
  • The latest agency policy developments, often before they're officially announced;
  • Major news insights, follow-ups and reactions in each product area;
  • Summaries of the latest Warning Letters;
  • The newest product approvals;
  • Summaries of the latest FDA Federal Register notices;
  • Summaries of DDMAC letters;
  • Related industry news capsules;
  • The industry's most concise FDA news index;
  • Inside-FDA news briefs
You can rely on FDA Review to provide only what's important - in the most convenient and time-saving